# Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

> **NCT00799552** · PHASE2 · COMPLETED · sponsor: **Resolvyx Pharmaceuticals, Inc** · enrollment: 232 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** RX-10045
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00799552
- **Lead sponsor:** Resolvyx Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-06
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2010-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00799552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00799552, "Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00799552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*